دورية أكاديمية
Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis.
| العنوان: | Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. |
|---|---|
| المؤلفون: | Penagos M; Allergy and Clinical Immunology, Division of Respiratory Science, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital Imperial College London, Dovehouse Street, London, SW3 6LY UK., Eifan AO; Allergy and Clinical Immunology, Division of Respiratory Science, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital Imperial College London, Dovehouse Street, London, SW3 6LY UK., Durham SR; Allergy and Clinical Immunology, Division of Respiratory Science, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital Imperial College London, Dovehouse Street, London, SW3 6LY UK., Scadding GW; Allergy and Clinical Immunology, Division of Respiratory Science, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital Imperial College London, Dovehouse Street, London, SW3 6LY UK. |
| المصدر: | Current treatment options in allergy [Curr Treat Options Allergy] 2018; Vol. 5 (3), pp. 275-290. Date of Electronic Publication: 2018 Aug 31. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Publishing AG Country of Publication: Switzerland NLM ID: 101626566 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2196-3053 (Print) NLM ISO Abbreviation: Curr Treat Options Allergy Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Cham, Switzerland] : Springer International Publishing AG, [2014]- |
| مستخلص: | Rationale: Subcutaneous and sublingual immunotherapy are effective for allergic rhinitis. An important question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. In view of potential side effects, cost and the necessary patient commitment, long-term benefit is an important consideration for the recommendation of immunotherapy over standard pharmacotherapy. Purpose of Review: In this review, we analyse the existing evidence for long-term effects of both routes of administration in the context of double-blind, placebo-controlled, randomised clinical trials that included a follow-up phase of at least 1 year after treatment cessation. Recent Findings: Overall, evidence suggests that 3 years of either subcutaneous or sublingual immunotherapy result in clinical benefit and immunological changes consistent with allergen-specific tolerance sustained for at least 2-3 years after treatment cessation. Summary: The data presented here support recommendations in international guidelines that both routes of administration should be continued for a minimum of 3 years. Gaps in the evidence remain regarding the long-term efficacy of immunotherapy for perennial rhinitis and studies performed in children. Competing Interests: SR Durham has received consultancy fees from manufacturers of allergy vaccines, including ALK Abello Denmark, Allergy Therapeutics UK, Anergis Switzerland, Asics Biotech Belgium, Biomay Austria, and from Boehringer Ingelheim Germany and Glaxo Smith Kline UK and lecture fees from Med Update GmBH Germany. GW Scadding has received lecture fees from ALK Abello Denmark and Glaxo Smith Kline UK. M Penagos has received personal fees from Stallergenes and ALK outside the submitted work. Aarif O. Eifan declares that he has no competing interests.This article contains reference to studies of clinical trials and mechanistic studies in human subjects undergoing allergen immunotherapy that were performed by the authors of this manuscript. All such studies were performed with approval of the national ethics committee in UK and with the written informed consent of the participants. |
| References: | BMJ. 1991 Feb 2;302(6771):265-9. (PMID: 1998791) J Allergy Clin Immunol. 2010 Nov;126(5):969-75. (PMID: 20934206) Allergy. 2017 Nov;72(11):1597-1631. (PMID: 28493631) Lancet. 2011 Dec 17;378(9809):2112-22. (PMID: 21783242) Allergy. 2018 Apr;73(4):739-743. (PMID: 29380390) J Allergy Clin Immunol. 2011 Sep;128(3):559-66. (PMID: 21802126) JAMA. 2017 Feb 14;317(6):615-625. (PMID: 28196255) Lancet. 2008 Sep 20;372(9643):1049-57. (PMID: 18805333) Eur Respir J. 2004 Nov;24(5):758-64. (PMID: 15516669) JAMA. 2017 Feb 14;317(6):591-593. (PMID: 28196239) Nat Rev Immunol. 2006 Oct;6(10):761-71. (PMID: 16998509) J Allergy Clin Immunol. 1997 Sep;100(3):293-300. (PMID: 9314339) J Allergy Clin Immunol. 2009 Sep;124(3 Suppl):S43-70. (PMID: 19592081) Clin Exp Allergy. 2017 Jul;47(7):856-889. (PMID: 30239057) Allergy. 1995 May;50(5):405-13. (PMID: 7573829) J Allergy Clin Immunol. 1984 Apr;73(4):484-9. (PMID: 6707391) Allergy. 1999 Apr;54(4):313-9. (PMID: 10371089) Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001936. (PMID: 17253469) Allergy. 2018 Apr;73(4):765-798. (PMID: 28940458) J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498. (PMID: 29221580) J Allergy Clin Immunol. 2014 Jun;133(6):1608-14.e6. (PMID: 24388010) N Engl J Med. 2015 Jan 29;372(5):456-63. (PMID: 25629743) J Allergy Clin Immunol. 2016 Feb;137(2):444-451.e8. (PMID: 26292778) Allergy. 2008 Apr;63 Suppl 86:8-160. (PMID: 18331513) N Engl J Med. 1999 Aug 12;341(7):468-75. (PMID: 10441602) J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. (PMID: 21122901) Pediatr Allergy Immunol. 2017 Feb;28(1):18-29. (PMID: 27653623) Clin Transl Allergy. 2015 May 22;5:12. (PMID: 26097680) Allergy. 2012 Mar;67(3):302-11. (PMID: 22150126) Clin Exp Allergy. 2003 Aug;33(8):1076-82. (PMID: 12911781) Int Arch Allergy Immunol. 2015;166(3):177-88. (PMID: 25895909) Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):586-93. (PMID: 21986550) Clin Exp Allergy. 2008 Jul;38(7):1074-88. (PMID: 18691292) J Laryngol Otol. 2018 Mar;132(3):230-235. (PMID: 29374499) J Allergy Clin Immunol. 2006 Feb;117(2):319-25. (PMID: 16461133) J Allergy Clin Immunol. 2016 Feb;137(2):339-349.e10. (PMID: 26853126) Clin Exp Allergy. 1998 Mar;28(3):266-70. (PMID: 9543074) J Allergy Clin Immunol. 2018 Feb;141(2):529-538.e13. (PMID: 28689794) Allergy. 2009 Sep;64(9):1394-401. (PMID: 19764942) Allergy. 2006 Feb;61(2):198-201. (PMID: 16409196) World Allergy Organ J. 2016 Oct 12;9(1):33. (PMID: 27777642) J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5. (PMID: 22285278) J Allergy Clin Immunol. 2010 Jan;125(1):131-8.e1-7. (PMID: 20109743) J Allergy Clin Immunol. 2006 Aug;118(2):434-40. (PMID: 16890769) J Allergy Clin Immunol. 2018 May;141(5):1750-1760.e1. (PMID: 29128670) Pediatr Allergy Immunol. 2017 Dec;28(8):728-745. (PMID: 28902467) Clin Exp Allergy. 2013 May;43(5):568-77. (PMID: 23600548) Allergy. 2007 Aug;62(8):943-8. (PMID: 17620073) |
| فهرسة مساهمة: | Keywords: Allergen immunotherapy; Allergic rhinitis; Biomarkers; Long term efficacy; Mechanisms; Subcutaneous; Sublingual |
| تواريخ الأحداث: | Date Created: 20180918 Latest Revision: 20230928 |
| رمز التحديث: | 20230928 |
| مُعرف محوري في PubMed: | PMC6132438 |
| DOI: | 10.1007/s40521-018-0176-2 |
| PMID: | 30221122 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2196-3053 |
|---|---|
| DOI: | 10.1007/s40521-018-0176-2 |